Pay in 4 interest-free payments of $5.35 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
According to the materials published on the official website, GSBR-1290 is undergoing a 12-week randomized, double-blind, placebo-controlled Phase 2a clinical trial to evaluate the therapeutic effect of the drug in patients with type 2 diabetes mellitus (T2DM) and obesity
Both belong to a new generation of injectable peptide-based therapies that work by targeting multiple hormonal pathways simultaneously, offering potentially greater metabolic benefits than earlier single-receptor agents
FAQ Is NAC safer than glutathione
Accessed on May 14, 2025 at Rizvi, A
Thank you again, dear Dr
US$ 26.54
US$ 26.70
US$ 29.00
US$ 20.88
